These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21924412)

  • 21. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
    Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
    Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Study on the relationship between breast cancer resistance protein expression and 5-fluorouracil resistance].
    Yuan JH; Cheng JQ; Ke YB; Ji NN; Zhou JM; Zhou L; Huang HY; Yang LQ; Liu JJ; Xu XY; Zhuang ZX
    Zhonghua Yu Fang Yi Xue Za Zhi; 2008 Jul; 42(7):506-10. PubMed ID: 19035187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A novel marker of multiple drug resistance BCRP].
    Bogush TA; Pokataev IA; Timofeeva NV; Ozherel'ev AS
    Antibiot Khimioter; 2003; 48(6):33-41. PubMed ID: 14558417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of conformation independent computational models for the early recognition of breast cancer resistance protein substrates.
    Gantner ME; Di Ianni ME; Ruiz ME; Talevi A; Bruno-Blanch LE
    Biomed Res Int; 2013; 2013():863592. PubMed ID: 23984415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.
    Fleisher B; Unum J; Shao J; An G
    J Pharm Sci; 2015 Jan; 104(1):266-75. PubMed ID: 25418056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
    Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of Drug Transfer into Milk Considering Breast Cancer Resistance Protein (BCRP)-Mediated Transport.
    Ito N; Ito K; Ikebuchi Y; Toyoda Y; Takada T; Hisaka A; Oka A; Suzuki H
    Pharm Res; 2015 Aug; 32(8):2527-37. PubMed ID: 25690342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
    Römermann K; Helmer R; Löscher W
    Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Classical resistance mechanisms.
    Jäeger W
    Int J Clin Pharmacol Ther; 2009 Jan; 47(1):46-8. PubMed ID: 19203536
    [No Abstract]   [Full Text] [Related]  

  • 34. Bifendate-chalcone hybrids: a new class of potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
    Gu X; Ren Z; Peng H; Peng S; Zhang Y
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):318-22. PubMed ID: 25446092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.
    Kowalski P; Wichert A; Holm PS; Dietel M; Lage H
    Cancer Gene Ther; 2001 Mar; 8(3):185-92. PubMed ID: 11332989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer.
    Yuan J; Lv H; Peng B; Wang C; Yu Y; He Z
    Cancer Chemother Pharmacol; 2009 May; 63(6):1103-10. PubMed ID: 18820913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
    Shen H; Lee FY; Gan J
    J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
    Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
    Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
    Ji N; Yuan J; Liu J; Tian S
    Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
    González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC
    J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.